We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No blarney

31 March 2005 By Robert Cyran

The Irish biotech is reeling after a third case of a rare disease has been linked to its lead drug Tysabri. The drug is as good as dead. This makes Elan s onerous debt load a crushing burden.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)